Dihydroxyphenylacetic Acid (DOPAC)

Most people never think about the chemicals their nerves use to send signals, but dopamine is one of the busiest. It controls movement, mood, blood pressure, and how the kidneys handle salt and water. When dopamine gets broken down, one of the leftovers is DOPAC (dihydroxyphenylacetic acid), and a fraction of it ends up in urine.

This is a research-grade marker, not a standard clinical test. It does not yet have universally agreed-upon cutoffs, and a single value will not diagnose anything on its own. What it can do is give you an early, exploratory look at a metabolic pathway most lab panels ignore, which is useful if you are tracking nervous system health, eating a lot of olive-derived polyphenols, or trying to understand how a dopamine-affecting medication is interacting with your body.

What DOPAC Actually Is

DOPAC is the product of a two-step breakdown of dopamine. An enzyme called monoamine oxidase (MAO, which breaks down nerve-signaling molecules) takes the first cut, and a second enzyme called aldehyde dehydrogenase (which clears toxic byproducts) finishes the job. DOPAC can then be modified again into another metabolite called homovanillic acid (HVA), so it sits in the middle of dopamine's disposal pathway.

In healthy people given a tagged dose of DOPAC, roughly 40% of it appears in urine within 24 hours as HVA, with smaller amounts as DOPAC itself and a few related acids. This means urine DOPAC reflects both what was just made and what made it through the body's chemical conversions without being further processed.

Why Urinary DOPAC Is Different from Brain DOPAC

This is the single most important point to understand before ordering this test. Most of the high-profile DOPAC research has been done in cerebrospinal fluid (the clear fluid around the brain and spinal cord) or in blood, not urine. Those measurements reflect dopamine activity in brain cells. Urinary DOPAC reflects something different.

The bulk of urinary dopamine and DOPAC comes from kidney cells, which take up a dopamine precursor called L-DOPA from the bloodstream and convert it into dopamine and then into DOPAC right inside the kidney. So your urinary DOPAC number is mostly telling you about kidney-level dopamine handling, with a smaller contribution from the dopamine circulating in your bloodstream from elsewhere. Findings about brain dopamine do not automatically apply to what shows up in your urine.

Parkinson's Disease and Autonomic Disorders

In Parkinson's disease and related conditions called autonomic synucleinopathies (a group of disorders affecting the body's automatic functions), urinary excretion of both dopamine and DOPAC is reduced compared to healthy controls. This is interpreted as a sign of dysfunction in the kidney's dopamine-handling system and in the nerves controlling involuntary functions. The strongest, clearest dopamine-deficiency findings still come from cerebrospinal fluid studies, where DOPAC distinguishes early Parkinson's disease with high sensitivity, but urinary measurements track related changes in the body's outer dopamine systems.

In one human study, DOPAC measured in cerebrospinal fluid (which is a different specimen than the urine this test uses) separated newly diagnosed Parkinson's disease from controls with 100% sensitivity and 89% specificity, and combined low DOPA plus DOPAC values predicted later Parkinson's disease in at-risk people with 75% sensitivity and 100% specificity over roughly three to four years. Whether urinary DOPAC carries the same predictive value has not been directly tested at that level.

Where Urinary DOPAC Does Not Help

If you are worried about an adrenal tumor called pheochromocytoma, this is not the test you want. A large clinical study evaluating biochemical diagnosis of pheochromocytoma found that simultaneous urinary DOPAC was not diagnostically useful. Urinary epinephrine and norepinephrine measurements do the diagnostic work for that condition, and DOPAC adds nothing.

What This Test Reflects in Real Life

Outside of disease, urinary DOPAC moves in response to two main things: how much dopamine your kidneys and circulation are processing, and how much olive-derived polyphenol you have consumed. The olive connection is biologically interesting. Hydroxytyrosol, a small molecule abundant in olive oil and olive pomace, gets metabolized through pathways that produce DOPAC and a DOPAC-sulfate. In a randomized trial of olive pomace-enriched biscuits, both urinary and blood DOPAC rose significantly after eight weeks of daily intake. That rise reflects polyphenol metabolism, not changes in your dopamine system.

This is why the same urinary DOPAC number can mean different things in different people. A high reading in someone who just ate a Mediterranean diet means something different than a high reading in someone on dopamine-affecting medication, which means something different again than a low reading in someone with autonomic symptoms.

When Results Can Be Misleading

• Olive polyphenol intake: heavy olive oil or hydroxytyrosol-rich foods within the days before testing can drive urinary DOPAC up substantially, because DOPAC is a known metabolite of hydroxytyrosol, not just of dopamine.
• Ethanol: progressive alcohol intake reduces the urinary DOPAC-to-hydroxytyrosol ratio, redirecting dopamine breakdown toward hydroxytyrosol production. Drinking in the day before a test can shift your numbers in ways unrelated to underlying biology.
• L-DOPA therapy: oral L-DOPA used in Parkinson's disease raises urinary DOPAC because the kidneys process much of the dose into dopamine and then into DOPAC. Levels during treatment do not reflect underlying dopamine system function the way an off-treatment level would.
• MAO inhibitor medications: the MAO-A inhibitor moclobemide reduced plasma DOPAC by up to about 75% in healthy volunteers. The urinary effect was directionally similar with decreases in deaminated metabolites. If you take an MAO inhibitor, your DOPAC reading will look artificially low.

Tracking Your Trend

Because this is a research-grade marker without firm reference cutoffs, a single reading carries less weight than a tracked pattern. The most useful approach is to establish your own personal baseline and then look at how it moves in response to deliberate changes. If you start eating more olive oil, your number should rise. If you stop, it should fall. If you begin a dopamine-modifying medication, you can watch how your kidneys respond.

A reasonable cadence is to get a baseline, then retest in three to six months if you are making meaningful dietary or medication changes, then at least annually if you want to track a trend over time. What you are watching for is consistency: a stable reading in one person who has not changed their habits suggests your kidney dopamine processing is steady. A sudden, unexplained drop while you are off polyphenol-rich foods and not on any inhibitor of dopamine metabolism is more interesting than any single number in isolation.

What an Out-of-Pattern Result Should Make You Do

Because this is exploratory, treat unexpected results as a prompt to look further, not as a verdict. The first move is to reconcile the result against your recent diet and medications. If you have been eating heavily Mediterranean, drinking alcohol, or taking any dopamine-related drug in the days before the test, repeat the measurement under cleaner conditions before reading anything into it.

If a low reading persists across multiple tests in someone with symptoms suggesting autonomic dysfunction, such as light-headedness on standing, constipation, or changes in sweating, that is the point at which a workup makes sense. Companion tests worth considering include a full urinary catecholamine panel covering dopamine, norepinephrine, and HVA, plus a clinical evaluation by a neurologist or autonomic specialist. Imaging and cerebrospinal fluid studies are reserved for situations where clinical concern is high. If you are evaluating an adrenal tumor concern, do not rely on DOPAC. Urinary epinephrine and norepinephrine plus plasma or urinary metanephrines are the established tests.